30 July 2026 • 3 minute read
DLA Piper advises Custom Health Holdings on reverse takeover, InnovativeRx acquisition, and TSX listing
DLA Piper advised Custom Health Holdings Inc. (Custom Health) on a series of strategic transactions, including its reverse takeover via plan of arrangement with Queue Ventures Ltd., its acquisition of InnovativeRX US Holdings, Inc.’s (InnovativeRX) operating assets, and commencement of trading on the Toronto Stock Exchange under the symbol CHLT.
InnovativeRx is an existing operational partner that previously utilized Custom Health’s technology and supported patient programs across multiple markets. The acquisition strengthens Custom Health's integrated pharmacy operations, clinical infrastructure, and operational footprint across the United States.
“These transactions advance our strategy to scale a technology-enabled care platform that improves medication adherence, strengthens clinical oversight, and delivers better outcomes for complex patient populations,” said Shane Bishop, Founder and CEO of Custom Health. “DLA Piper’s practical guidance and execution capabilities helped us move efficiently through a pivotal period and positioned us to continue growing across North America.”
“We are grateful for the opportunity to work with Custom Health on this significant milestone in the company’s growth,” said Mitchell Marder, DLA Piper Senior Counsel who co-led the deal. “It has been a privilege to collaborate with Shane Bishop and the Custom Health team over the last six years, and we appreciate the trust they have placed in us as they continue to expand their market presence and healthcare technology platform.”
DLA Piper’s cross-border, multidisciplinary deal team was co-led by Marder (Washington, DC) in the US and Partners Russel Drew and Jamie Mandell (both Toronto) in Canada. The team also included Partners Richard Marks (Washington, DC) and Kevin Fritz (Toronto), as well as Associates Melissa Lucar (Los Angeles), Brendan Smith (Toronto), and Fayzaan Naeem (Palo Alto). The DLA Piper team also counseled on equity and debt financings.
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 16 consecutive years by Mergermarket.
With over 400 life sciences professionals worldwide, DLA Piper deliver seamless, tailored solutions across every stage of the business lifecycle. Our team includes medical doctors, PhDs, and industry veterans who bring extensive scientific and legal knowledge and experience to every challenge. We combine modern insights with an expansive geographic footprint to help clients anticipate risk, maximize opportunity, and stay ahead in a rapidly evolving landscape. Whether navigating complex regulations or defending innovation, we work as one—offering bold, agile strategies and value-added counsel that keep science on your side.
InnovativeRx is an existing operational partner that previously utilized Custom Health’s technology and supported patient programs across multiple markets. The acquisition strengthens Custom Health's integrated pharmacy operations, clinical infrastructure, and operational footprint across the United States.
“These transactions advance our strategy to scale a technology-enabled care platform that improves medication adherence, strengthens clinical oversight, and delivers better outcomes for complex patient populations,” said Shane Bishop, Founder and CEO of Custom Health. “DLA Piper’s practical guidance and execution capabilities helped us move efficiently through a pivotal period and positioned us to continue growing across North America.”
“We are grateful for the opportunity to work with Custom Health on this significant milestone in the company’s growth,” said Mitchell Marder, DLA Piper Senior Counsel who co-led the deal. “It has been a privilege to collaborate with Shane Bishop and the Custom Health team over the last six years, and we appreciate the trust they have placed in us as they continue to expand their market presence and healthcare technology platform.”
DLA Piper’s cross-border, multidisciplinary deal team was co-led by Marder (Washington, DC) in the US and Partners Russel Drew and Jamie Mandell (both Toronto) in Canada. The team also included Partners Richard Marks (Washington, DC) and Kevin Fritz (Toronto), as well as Associates Melissa Lucar (Los Angeles), Brendan Smith (Toronto), and Fayzaan Naeem (Palo Alto). The DLA Piper team also counseled on equity and debt financings.
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 16 consecutive years by Mergermarket.
With over 400 life sciences professionals worldwide, DLA Piper deliver seamless, tailored solutions across every stage of the business lifecycle. Our team includes medical doctors, PhDs, and industry veterans who bring extensive scientific and legal knowledge and experience to every challenge. We combine modern insights with an expansive geographic footprint to help clients anticipate risk, maximize opportunity, and stay ahead in a rapidly evolving landscape. Whether navigating complex regulations or defending innovation, we work as one—offering bold, agile strategies and value-added counsel that keep science on your side.